Journal of Pharmacology Pharmaceutics & Pharmacovigilance Category: Medical Type: Short Commentary

Anosmia in COVID-19: Celecoxib Appears to Speed Recovery

Tomera KM1* and Joseph K Kittah1
1 Pulmonary and critical care medicine, Beloit Memorial Hospital, 1905 E Huebbe Parkway, Beloit Wisconsin 53511, United states

*Corresponding Author(s):
Tomera KM
Pulmonary And Critical Care Medicine, Beloit Memorial Hospital, 1905 E Huebbe Parkway, Beloit Wisconsin 53511, United States

Received Date: Nov 30, 2020
Accepted Date: Dec 17, 2020
Published Date: Dec 24, 2020


Abrupt loss of smell (anosmia) is recognized as one of the frequent hallmarks of Covid-19. While it usually recovers within weeks, it may not. Both the SARS-CoV-2 spike protein and nucleocapsid N protein upregulate COX-2. Patients suffering COVID-19 disease often present with markedly elevated levels of Prostaglandin E2 (PGE2). Rapid return of smell in 2-5 days was observed after increasing the dose of celecoxib to 400mg oral twice daily (BID) with high dose famotidine 80mg four times a day (QID) as adjuvant therapy for COVID-19.  Magnetic resonance imaging- MRI have shown changes in the olfactory bulbs in patients with anosmia. Consistent with local inflammation, only minor changes in inflammatory markers were sometimes noted when tested. Adjuvant therapy with high dose celecoxib and high dose famotidine appears to be promising and should be studied for this disturbing symptom of Covid-19 and other CNS COVID-19 sequalae.


Anosmia; Antihistamine; Celecoxib; Covid-19; Cyclooxygenase inhibitors; Famotidine


Reduction of smell is recognized as one the cardinal symptoms of Covid-19 [1]. Unfortunately, while in most cases return of smell occurs as rapidly as the loss of smell in several weeks too frequently anosmia persists for even months [2]. 

Both the SARS-CoV-2 spike protein and nucleocapsid N protein upregulate COX-2 [3-5]. Patients suffering COVID-19 disease often present with markedly elevated levels of Prostaglandin E2 (PGE2). A prospective study of adjuvant therapy with celecoxib has moderated covid-19 PGE-2 levels, prevented clinical deterioration and has had rapid improvement in CT-chest [6]. A retrospective study showed adjuvant therapy with celecoxib significantly improved IL-6 serum levels and appeared to improve outcomes [7]. An inclusive consecutive case series of adjuvant therapy with celecoxib in hospitalized patients showed significant clinical responses [8]. Increasing the celecoxib dose to 400mg bid oral appeared to improve clinical response [9].


Three patients with anosmia and positive PCR tests, one inpatient and two outpatients, given celecoxib 400mg bid oral and famotidine 80mg qid reported recovery of smell in two, three and five days. The inflammatory markers were minimally elevated with baseline biomarkers in the patient tested having a normal d-dimer, ferritin, lactate dehydrogenase, interleukin 6, neutrophil count, lymphocyte count, neutrophil lymphocyte ratio, comprehensive metabolic panel with only a slightly elevated C-reactive protein of 1.6 (normal <0.5pg/ml) and reduced total WBC of 2.4 (normal low 4.1 x 103/microliter to normal high 10.4 x103/microliter).


The minimal change in biomarkers measured in the patient presenting with anosmia suggest that anosmia is a local inflammation not requiring major systemic dysregulation. This appears to be supported by Magnetic Resonance Imaging (MRI) at presentation of COVID-19 patients with anosmia showed transient olfactory bulb edema [10]. Celecoxib has previously been shown to suppress experimental encephalomyelitis through prostaglandin and non-COX-2 pathways [11-13]. 

However, while celecoxib is hydrophobic and crosses the blood brain barrier it appears to require larger doses explaining why patients at celecoxib 200mg oral bid did not report rapid return of smell [14]. Fortunately, high dose celecoxib, 400mg oral bid for up to six months has been shown to be as safe as low dose celecoxib 100 mg oral bid and as safe as placebo [15]. Adjuvant therapy with celecoxib 400mg oral bid appears safe and promises to mitigate a bothersome symptom of COVID-19 -anosmia and deserves more investigation for not only anosmia but other CNS related COVID-19 sequalae.






  1. Cooper KW, Brann DH, Farruggia MC (2020) COVID-19 and the chemical senses: supporting players take center stage. Neuron 107: 219-233.
  2. Hopkins C, Surda P, Whitehead E (2020) Early recovery following new onset anosmia during the COVID-19 pandemic - an observational cohort study. J of Otolaryngology - Head & Neck Surg 49:
  3. Yan X, Hao Q, Mu Y, Timani KA, Ye L, et al. (2006) Nucleocapsid protein of SARS- CoV activates the expression of cyclooxygenase-2 by binding directly to regulatory elements for nuclear factor-kappa B and CCAAT/enhancer binding protein. Int J Biochem Cell Biol 38: 1417-1428.
  4. Liu M, Yang Y, Gu C, Yue Y, Wu KK, et al. (2007) Spike protein of SARS-CoV stimulates cyclooxygenase-2 expression via both calcium-dependent and calcium- independent protein kinase C pathways. FASEB J 21: 1586-1596.
  5. Chen JS, Alfajaro MM, Wei J, Chow RD, Filler RB, et al. (2020) Cyclooxgenase-2 is induced by SARS-CoV-2 infection but does not affect viral entry or replication. bioRxiv.
  6. Hong W, Chen Y, You K, Tan S, Wu F, et al. (2020) Celebrex Adjuvant Therapy on Coronavirus Disease 2019: An Experimental Study. Frontiers in Pharmacology 11: 1795.
  7. Ong SWX, Tan WYT, Chan YH, Fong SW, Renia L, et al. (2020) Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019. Clin Transl Immunology 9:
  8. Tomera K, Malone R, Kittah J (2020) Hospitalized COVID-19 Patients Treated with Celecoxib and High Dose Famotidine Adjuvant Therapy Show Significant Clinical Responses.
  9. Tomera KM, Malone RW, Kittah JK (2020) Brief Report: Rapid Clinical Recovery from Severe COVID-19 with High Dose Famotidine and High Dose Celecoxib Adjuvant Therapy. Enliven: Pharmacovigilance and Drug Safety 6: 20.
  10. Laurendon T, Radulesco T, Mugnier J (2020) Bilateral transient olfactory bulbs edema during COVID-19 related anosmia. Neurology 95: 224-225.
  11. Ni J, Shu YY, Zhu YN, Fu YF, Tang W, et al. (2007) COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL-10 production by inhibiting T-bet expression. J Neuroimmunology 186: 94-103.
  12. Reder AT, Thapar M, Sapugay AM, Jensen MA (1994) Prostaglandins and inhibitors of arachidonate metabolism suppress experimental allergic encephalomyelitis. J Neuroimmunology 54: 117-127.
  13. Miyamoto K, Miyake S, Mizuno M, Oka N, Kusunoki S, et al. (2006) Selective COX-2-inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway. Brain 129: 1984-1992.
  14. Dembo G, Park SB, Kharasch ED (2005) Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology 102: 409-415.
  15. Steinbach G, Lynch PM, Phillips RK (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952.


Citation: Tomera KM, Kittah JK (2020) Anosmia in COVID-19: Celecoxib Appears to Speed Recovery. J Pharmacol Pharmaceut Pharmacovig 4: 030.

Copyright: © 2020  Tomera KM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Herald Scholarly Open Access is a leading, internationally publishing house in the fields of Sciences. Our mission is to provide an access to knowledge globally.

© 2024, Copyrights Herald Scholarly Open Access. All Rights Reserved!